Hybrid Adenoviral Vector Systems for Personalized Medicine and Immune Response Monitoring

The present invention discloses a novel integration of adenoviral vectors derived from chimpanzee adenovirus AdY25 with distinct technologies such as blockchain, artificial intelligence, nanomaterials, and IoT-enabled biosensors to create powerful systems for personalized medicine and real-time immune response monitoring.

Traditional adenoviral vector-based vaccines have limitations in terms of efficacy, scalability, and patient response tracking. The original patent addressed some of these limitations by providing novel adenoviral vectors derived from chimpanzee adenovirus AdY25. However, there remains a need for more sophisticated systems that can integrate these vectors with emerging technologies to provide more effective and personalized treatments.

The inventive concept disclosed herein comprises a hybrid adenoviral vector system that combines the advantages of adenoviral vectors derived from chimpanzee adenovirus AdY25 with blockchain-based data management platforms, artificial intelligence-driven predictive modeling, nanomaterial-based delivery systems, and IoT-enabled biosensors. The system enables personalized medicine by tracking patient responses and optimizing treatment regimens in real-time. Additionally, the system can predict vaccine efficacy using a combination of adenoviral vector-based immunogenic compositions and artificial intelligence-driven predictive modeling.

The novelty of the present invention lies in the synergistic integration of adenoviral vectors with distinct technologies to create a more powerful system for personalized medicine and immune response monitoring. The inventive step resides in the recognition that these technologies can be combined in a way that provides a more effective and efficient system for vaccine development and patient treatment.

Alternative embodiments of the inventive concept may include the use of different adenoviral vectors, blockchain platforms, artificial intelligence algorithms, nanomaterials, and IoT-enabled biosensors. Variations of the system may also include the integration of additional technologies such as gene editing tools or synthetic biology approaches.

The inventive concept has significant commercial potential in the fields of personalized medicine, vaccine development, and immune response monitoring. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers seeking to develop more effective and targeted treatments for various diseases and conditions.